Follow on Google News News By Tag * Chinese diabetes market * Chinese insulin market * Non insulin diabetes market * DPP-IV Inhibitor * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Rising Diabetes Epidemic offering huge Opportunities for Drug Manufacturers in ChinaWith the Chinese population getting richer, fatter and less mobile; there has been a surge in the prevalence of diabetes in recent years
By: Krishna sharma The increasing prevalence of diabetes is ringing alarm bells for the government and healthcare agencies. For Drug manufacturers, however, this represents a huge opportunity. The report expects the combined sales of oral antidiabetics and insulin to grow at a CAGR of 28%, exceeding revenues worth US$ 2.8 Billion by 2015. IMARC’s new report “China Diabetes Market Outlook (2010-2015)” gives a deep insight into the Chinese diabetes market. The research study serves as an analytical as well as statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in China. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Chinese diabetes market in some form or the other. Forecasts: The report provides forecasts on: • Number of diabetes patients • Diagnosis and treatment rates in China • Diabetes market • Non-Insulin Anti-diabetics market Alpha- Glinides Glitazones Sulphonylureas DPP-IV Inhibitors Biguanides GLP-1 Agonists All other Non-Insulin Anti-diabetic classes • Insulin market Competitive Landscape: This section covers: • 2005-2009 sales and market shares of top players in the diabetes market • 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market • 2005-2009 sales and market shares of top players in various Non-Insulin Drug Classes • 2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin Drug Classes • 2005-2009 sales and market shares of top players in the Insulin market • 2005-2009 sales of top drugs comprising the portfolio of Key players in the Insulin market. Key Questions Answered in this report • What is the total size of the diabetes population in China and what are its characteristics? • What are the diagnosis and drug treatment rates for diabetes in China? • What are the key factors driving the growth of diabetes medication in China? • What is the Size and Breakup of the total diabetes market in China? • What is the Size and Breakup of the total Non-Insulin Anti-diabetics market in China? • What is the Size and Breakup of the total Insulin market in China? • Who are the key players in the Chinese diabetes market and how have they performed? • What is the outlook of the Chinese diabetes market in the next five years? • Which new products are expected to be launched in the next five years? • Which therapy classes will show the highest growth in the next five years? • What are the road blocks in the Chinese diabetes market? To obtain the complete report, please contact: IMARC Group Asia Email: apac@imarcgroup.com Phone: +91-120-425- IMARC Group North America Email: america@ Phone: +1-631-791-1145 To know more please visit: http://www.imarcgroup.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|